U.S. house committee to investigate FDA over CBD rulemaking

The Oversight Committee of the U.S. House of Representatives says it will investigate the U.S. Food and Drug Administration (FDA) over its regulatory jurisdiction of hemp-derived CBD.

The committee is expected to bring FDA Commissioner Robert Califf before the House, said Rep. James Comer, a Kentucky Republican who chairs the panel.

Stakeholders have criticized slow progress on federal CBD rules at the FDA, which has repeatedly said more research is needed on the safety and efficacy of CBD products.

Read More